<DOC>
	<DOCNO>NCT01735240</DOCNO>
	<brief_summary>The main purpose study compare change AZD5069 Pharmacokinetic profile administer ketoconazole . Subjects treat first AZD5069 follow washout period start combine treatment ( ketoconazole AZD5069 ) .</brief_summary>
	<brief_title>Phase I Study Assess Effect Healthy Male Volunteers Ketoconazole Pharmacokinetics Single Dose AZD5069 Administered Orally .</brief_title>
	<detailed_description>An open-label , fixed-sequence , single-centre phase I study assess effect ketoconazole pharmacokinetics AZD5069 oral administration single dose AZD5069 healthy male volunteer</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy male volunteer age 18 50 year ( inclusive ) . Veins suitable cannulation repeat venipuncture . Healthy volunteer neutrophil count within laboratory normal reference range Screening Body mass index ( BMI ) ≥18.0 ≤30.0 kg/m2 calculate height weight screening ; minimum weight 50 kg maximum weight 100 kg . Nonsmokers exsmokers smoke history last 3 month prior screen smoke history le 10 pack year ( 1 pack year = tobacco consumption correspond 20 cigarette smoke per day 1 year ) screening . Healthy volunteer latent tuberculosis suggest history judge Investigator Healthy volunteer belong highrisk group HIV infection . Known suspected history significant drug abuse judge Investigator . History alcohol abuse excessive intake alcohol judge Investigator . Plasma donation within 1 month screen blood donation/blood loss &gt; 500 mL 3 month and/or 1350 mL within 12 month prior screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase I ,</keyword>
	<keyword>healthy volunteer ,</keyword>
	<keyword>fixed-sequence ,</keyword>
	<keyword>open-label ,</keyword>
	<keyword>ketoconazole ,</keyword>
	<keyword>combination ,</keyword>
	<keyword>safety</keyword>
</DOC>